Journal
ANNALS OF ONCOLOGY
Volume 16, Issue 1, Pages 158-161Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdi016
Keywords
-
Categories
Ask authors/readers for more resources
E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available